Q4 2022 Targovax ASA Earnings Call Transcript
Welcome to Targovax and the presentation of our Q4 results for 2022. My name is Erik Digman Wiklund, and I'm the CEO at Targovax. During 2022, we have made important progress on all of our R&D programs, and this sets us up for success in 2023.
For the ONCOS-102 program, our lead clinical asset, we've published promising phase 1 results in prestigious journals and scientific conferences. And based on these strong data, we're now preparing to set up a phase 2 trial to demonstrate and validate these data in a larger setting. This trial is called SOPHOS-213. Preparations are going forward according to plan, and we're planning to open up prestigious cancer centers in the USA and Europe later this year for enrollment of patients.
Second, circular RNA. We've established a new cutting-edge circular RNA program from scratch. We have hired the discover of circular RNA, Dr. Thomas Hansen, and he is running this program for us. In just 12 months, we've achieved technical proof of concept for our vector delivery system, and in addition, we have filed
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investorsā 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
